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A B S T R A C T
Background
Clozapine is an efficacious treatment for treatment-resistant schizophrenia; however its use can be limited by side effect intolerability.
Sinus tachycardia is a common adverse event associatedwith clozapine treatment. Various pharmacological treatments are used to control
heart rate increase due to clozapine use and can include a decreased rate of clozapine titration, a switch to a different antipsychotic, or
treatment with negative chronotropic drugs.
Objectives
To assess the clinical effects and efficacy of pharmacological interventions for clozapine-induced sinus tachycardia.
To systematically review the adverse events associated with pharmacological interventions for clozapine-induced sinus tachycardia.
Search methods
On 23March 2015, we searched the Cochrane Schizophrenia Group’s Study-Based Register of Trials, which is based on regular searches
of CINAHL, BIOSIS, AMED, EMBASE, PubMed, MEDLINE, PsycINFO and registries of clinical trials. There are no language,
date, document type or publication status limitations for inclusion of records in the register.
Selection criteria
Randomised controlled trials comparing pharmacological interventions, at any dose and by any route of administration, for clozapine-
induced tachycardia.
Data collection and analysis
We independently screened and assessed studies for inclusion using pre-specified inclusion criteria.
Main results
The electronic searches located three references. However, we did not identify any studies that met our inclusion criteria.
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Authors’ conclusions
With no studies meeting the inclusion criteria, it is not possible to arrive at definitive conclusions. There are currently insufficient data
to confidently inform clinical practice. We cannot, therefore, conclude whether specific interventions, such as beta-blockers, are less
effective or more effective than standard courses of alternative treatments for tachycardia. This lack of evidence for the treatment of
clozapine-induced tachycardia has implications for research and practice. Well-planned, conducted and reported randomised trials are
indicated. One trial is currently underway. Current practice outside of well-designed randomised trials should be clearly justified.
P L A I N L A N G U A G E S U M M A R Y
Pharmacological interventions for clozapine-induced sinus tachycardia
Clozapine is an antipsychotic medication used in the treatment of schizophrenia. Clozapine is the only treatment proven to be effective
for those people who do not respond to other antipsychotic medications. A fast pulse rate (tachycardia) is one of the more common
side effects associated with clozapine use. It is reported to occur in 25 out of every 100 people treated with clozapine. The occurrence
of a fast pulse rate may lead to palpitations in the person treated with clozapine, which can be unpleasant and worrying. A fast pulse
rate by itself is not necessarily dangerous to the person and can be treated. There are medications available to treat a fast pulse rate and
slow it down to a normal rate. Examples of such medications include beta-blockers and calcium channel blockers. However, a fast pulse
rate can lead to clozapine being stopped by doctors.
This review is about ways to reduce this problem, to find out if any treatment for a fast heart rate with clozapine use is better than
another. This review investigated the best available evidence for interventions aimed at treating a fast heart rate associated with clozapine
treatment. Unfortunately, we found no studies that could be included. Nevertheless, this review raises many unanswered questions and
strongly suggests that future research on the treatment is much needed. Finding answers to this question will aid people treated with
clozapine, and their doctors, in ensuring that a fast heart rate with clozapine can be treated and that clozapine can be safely continued.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Pharmacological interventions for clozapine- induced sinus tachycardia
Patient or population: adults with schizophrenia or related disorders treated for clozapine-induced tachycardia
Setting: any
Intervention: one pharmacological treatment for tachycardia
Comparison: another pharmacological treatment for tachycardia or placebo or no treatment
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with another phar-
macological treatment
for tachycardia or
placebo or no treat-
ment
Risk with one pharma-
cological treatment for
tachycardia
Clinical improvement in
pulse rate
Assessed with: pulse
rate
Study populat ion Not est imable - - We found no trial data
for this series of impor-
tant outcomes0 per 1000 0 per 1000
(0 to 0)
Improvement in heart
rate assessed with ECG
measurement
- The mean improve-
ment in heart rate as-
sessed with ECG mea-
surement in the inter-
vent ion group was 0 (0
to 0)
- - - No trial data
Durat ion of hospitalisa-
t ion
Study populat ion Not est imable - - No trial data
0 per 1000 0 per 1000
(0 to 0)
Clinically important ad-
verse events
Study populat ion Not est imable - - No trial data
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0 per 1000 0 per 1000
(0 to 0)
Pat ient sat isfact ion Study populat ion Not est imable - - No trial data
0 per 1000 0 per 1000
(0 to 0)
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: conf idence interval; ECG: electrocardiogram
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
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B A C K G R O U N D
Schizophrenia is a severe and chronicmental illness. Treatment-re-
sistant schizophrenia occurs in aminority of peoplewhose response
to antipsychotic medication is suboptimal. Clozapine is the only
drug with established efficacy in treatment-resistant schizophre-
nia (Chakos 2001; Kane 1988; McEvoy 2006; Meltzer 2005; Siris
2001; Wahlbeck 1999). Further, it has been demonstrated to re-
duce mortality rates, both in comparison with past users of cloza-
pine (Walker 1997), and when compared to other antipsychotics
(Tiihonen 2009). The exceptional position held by clozapine in
the pharmacopoeia for treatment-resistant schizophrenia means
that adverse events secondary to its usage must be minimised and
aggressively treated when they occur. This is in order to reduce
morbidity and maximise adherence with clozapine, particularly
since adverse effects are a frequent reason for clozapine discontin-
uation (Pai 2012; Taylor 2009).
Description of the condition
Sinus tachycardia is one of the more common adverse events and
is reported to occur in 25% of patients treated with clozapine
(Lieberman 1998; Safferman 1991). The development of tachy-
cardia is generally considered to be a transient, benign occurrence
(Young 1998), which may be related to the rapid dose titration of
clozapine (Marinkovic 1994;Merrill 2005). Rapid clozapine titra-
tion rates (to 300 mg over one week) have been associated with
increased pulse rates of 20 to 25 beats/minute (Sandoz 1987). In
medication-free healthy volunteers, clozapine, at a relatively low
dose of 50 mg, has been shown to cause a significant mean in-
crease in heart rate of 14.3 beats/minute greater than that caused
by placebo (Pretorius 2001). Patients with schizophrenia, taking
clozapine at daily doses of 300 mg to 700 mg, have been shown
to have significantly higher heart rates (mean 107 beats/minute)
than patients treated with haloperidol (86 beats/minute) or olan-
zapine (89 beats /minute) or unmedicated healthy controls (mean
62 beats/minute) (Cohen 2001). For some patients, the clozap-
ine-induced sinus tachycardia persists and is symptomatic, neces-
sitating further investigation and consideration of interventions
to control it.
Description of the intervention
Various effective treatmentsmay exist to control heart rate increase
due to clozapine use and can include decreased rate of clozapine
titration (Safferman 1991), a switch to a different antipsychotic
(Cohen 2001), or treatment with negative chronotropic drugs.
How the intervention might work
The intervention would work by reducing the heart rate and
any symptoms, such as palpitations, which may occur with an
increased heart rate. Interventions to manage sinus tachycardia
associated with clozapine include dose reduction, a decreased
rate of clozapine titration (Safferman 1991), a switch to a dif-
ferent antipsychotic (Cohen 2001), or treatment with negative
chronotropic drugs. Traditionally, beta-blockers are themost com-
monly used agents that are used to reduce the heart rate and work
by blocking peripheral beta receptors, dampening sympathetic hy-
peractivity and increasing parasympathetic activity (Stryjer 2009).
In patients with coronary heart disease, reducing the heart rate is
a generally accepted treatment modality; it directly minimises the
myocardial oxygen demand and enhances its supply by improving
subendocardial blood flow (Cook 2007; Diaz 2005).
Why it is important to do this review
Clozapine-induced sinus tachycardia seems to be problematic
in the early stages of treatment and is probably dose-related
(Lieberman 1998; Merrill 2005). It is important that adverse
events due to clozapine use are managed appropriately, in order to
minimise unnecessary clozapine discontinuation. Sinus tachycar-
dia is an identified reason for clozapine discontinuation, but the
frequency of clozapine discontinuation secondary to tachycardia
has not been widely described. In a 15-year naturalistic retrospec-
tive study of clozapine use, tachycardia was identified as the cause
of discontinuation in 4% of clozapine users (Davis 2014). While
cardiovascular events have been identified as the most common
cause of deaths during treatment with clozapine (Davis 2014), and
the occurrence of myocarditis or cardiomyopathy should prompt
the immediate discontinuation of clozapine, the emergence of
an isolated sinus tachycardia (provided that myocarditis is ruled
out) should not be a cause for clozapine discontinuation (Nielsen
2013), and should be appropriately managed.
Substantial epidemiological evidence shows resting sinus tachy-
cardia to be a risk factor for coronary artery disease and cardiovas-
cular morbidity and mortality (Borer 2008; Diaz 2005; Kannel
1987), comparable to that of hypertension and dyslipidaemia. Si-
nus tachycardia is associated with both greater myocardial oxy-
gen consumption and decreased myocardial perfusion, the latter
by shortening the duration of diastole, which can induce or exac-
erbate myocardial ischaemia (Diaz 2005). An elevated heart rate
is also strongly associated with mortality in the general popula-
tion (Cook 2007). Individuals with established psychosis have in-
creased mortality rates compared to the general population due
to cardiovascular disease, necessitating the minimisation of car-
diovascular risk factors, such as sinus tachycardia, in this popula-
tion. An ongoing resting sinus tachycardia is also recognised as a
risk factor for cardiomyopathy (Shinbane 1997), a serious adverse
event associated with clozapine treatment. The need to minimise
the risk of cardiac adverse events secondary to clozapine use and to
reduce the risk of cardiovascular morbidity are pertinent reasons
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for the symptomatic treatment of sinus tachycardia in clozapine-
treated patients.
Various pharmacological approaches have been used to try to al-
leviate this problem, however, to the best of our knowledge there
are no drug treatments licensed for this indication.
Effective treatments may exist to control the increase in heart
rate due to clozapine use and we intended to evaluate studies to
discover whether evidence of effective proven treatments exists. A
systematic review of pharmacological interventions for clozapine-
induced sinus tachycardia has yet to be carried out. A systematic
review on this subject would bring together completed studies in
this area, to aid in making clinical decisions and guiding future
research.
O B J E C T I V E S
To assess the clinical effects and efficacy of pharmacological inter-
ventions for clozapine-induced sinus tachycardia.
To systematically review the adverse events associated with phar-
macological interventions for clozapine-induced sinus tachycar-
dia.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All relevant randomised controlled trials. If a trial was described as
’double-blind’ but implied randomisation, we planned to include
such trials in a sensitivity analysis (Sensitivity analysis). If their
inclusion did not result in a substantive difference, they were to
remain in the analyses. If their inclusion did result in important,
clinically significant but not necessarily statistically significant dif-
ferences, we planned not to add the data from these lower quality
studies to the results of the better trials, but would have presented
such data within a subcategory. We also decided to exclude quasi-
randomised studies, such as those allocating by alternate days of
the week. Where people were given additional treatments within
the treatment intervention, we planned to only include data if the
adjunct treatment was evenly distributed between groups and it
was only the treatment intervention that was randomised.
Types of participants
Adults, however defined, with schizophrenia or related disorders,
including schizophreniform disorder, schizoaffective disorder and
delusional disorder, again by any means of diagnosis, who have
been treated with clozapine irrespective of gender, age or diagno-
sis. No specific duration of clozapine treatment was required. All
participants needed to have evidence of a heart rate greater than
100 beats/minute with a documented sinus tachycardia, judged to
be clozapine-induced.
We are interested in making sure that information is as relevant
to the current care of people with schizophrenia as possible so
we proposed to clearly highlight the current clinical state (acute,
early post-acute, partial remission, remission). In future searches
for trials, we will largely classify individuals as meeting the criteria
for treatment-resistant schizophrenia or psychosis, as it is only for
this treatment-resistant group of patients that clozapine is used as
a licensed treatment.
Types of interventions
1. Pharmacological intervention
Any pharmacological intervention at any dose or route of admin-
istration the primary aim of which is to treat clozapine-induced
tachycardia.
Compared with:
2. Control
Another pharmacological agent, placebo or no treatment.
Types of outcome measures
All outcomes were to be divided into short-term (up to 12 weeks),
medium-term (13 to 26 weeks) and long-term (more than 26
weeks).
Primary outcomes
The primary measure of efficacy is clinical improvement in pulse
rate, measured either as a dichotomous outcome (proportions of
patients with treatment response as defined by each of the studies),
or as a continuous outcome (reported either as an endpoint score
or change in pulse rate from baseline to endpoint).
1. Measurement of pulse rate
1.1 Normalisation of pulse rate (as defined by a pulse rate of less
than 100 beats/minute or by the individual studies)
1.2 Clinically important change in pulse rate (as defined by the
individual studies)
1.3 Mean change in pulse rate documented by electrocardiogram
(ECG) or from case record
1.4 Mean endpoint pulse rate documented by ECG or from case
record
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Secondary outcomes
1. ECG measurement
1.1 Heart rate and rhythm
1.2 QTc interval
1.3 T-wave morphology
1.4 Other ECG markers
2. Service outcomes
2.1 Hospitalisation
2.2 Duration of hospitalisation
2.3 Time to hospitalisation
3. Global state
3.1 Relapse (as defined in trial)
3.2 Clinically important change in global state (as defined by in-
dividual studies)
3.3 Average endpoint global state score
3.4 Average change in global state scores
4. Mental state (with particular reference to the positive and
negative symptoms of schizophrenia)
4.1 Clinically important change in general mental state
4.2 Average endpoint general mental state score
4.3 Average change in general mental state scores
4.4 Clinically important change in specific symptoms (positive
symptoms of schizophrenia, negative symptoms of schizophrenia,
depression, mania)
4.5 Average endpoint specific symptom score
4.6 Average change in specific symptom scores
5. General functioning
5.1 Clinically important change in general functioning
5.2 Average endpoint general functioning score
5.3 Average change in general functioning scores
5.4 Clinically important change in specific aspects of functioning,
such as social or life skills
5.5 Average endpoint specific aspects of functioning, such as social
or life skills
5.6 Average change in specific aspects of functioning, such as social
or life skills
6. Adverse effects - general and specific
6.1 Clinically important general adverse effects
6.2 Average endpoint general adverse effect score
6.3 Average change in general adverse effect scores
6.4 Clinically important specific adverse effects
6.5 Average endpoint specific adverse effects (including endpoint
blood pressure (BP))
6.6 Average change in specific adverse effects (including change in
BP)
6.7 Sudden and unexpected death
7. Satisfaction with treatment
7.1 Leaving the studies early
7.2 Recipient of care not satisfied with treatment
7.3 Recipient of care average satisfaction score
7.4 Recipient of care average change in satisfaction scores
7.5 Carer not satisfied with treatment
7.6 Carer average satisfaction score
7.7 Carer average change in satisfaction scores
8. Quality of life (recipient or informal carers or professional
carers)
8.1 Clinically important change in overall quality of life
8.2 Average endpoint quality of life score
8.3 Average change in quality of life scores
8.4 Clinically important change in specific aspects of quality of
life
8.5 Average endpoint specific aspects of quality of life
8.6 Average change in specific aspects of quality of life
9. ’Summary of findings’ table
We planned to use the GRADE approach to interpret findings
(Schünemann 2008), and to use GRADE profiler (GRADEPRO)
to import data fromRevMan 5 (Review Manager) to create ’Sum-
mary of findings’ tables. These tables provide outcome-specific
information concerning the overall quality of evidence from each
included study in the comparison, the magnitude of effect of the
interventions examined, and the sum of available data on all out-
comes we rate as important to patient care and decision-making.
We aimed to select the following main outcomes for inclusion in
the ’Summary of findings’ table.
1. Measurement of pulse rate
2. ECG measurement
3. Service outcomes
4. Global state
5. Mental state (with particular reference to the positive
symptoms of schizophrenia)
6. Adverse effects - specific, such as hypotension and
bradycardia
7. Satisfaction with treatment
Search methods for identification of studies
Electronic searches
7Pharmacological interventions for clozapine-induced sinus tachycardia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
1. Cochrane Schizophrenia Group’s Trials Register
On 23 March 2015, the Trials Search Co-ordinator (TSC)
searched the Cochrane Schizophrenia Group’s Register of Trials
using the following phrase:
((clozapin* or clozaril* or denzapin* or zaponex* or alemoxan or
azaleptin or clopine or clopsine or dorval or dozapine or elcrit or
fazaclo or “hf 1854” or hf1854 or lapen?x or lozapin* or sizopin or
versacloz or zapen) and (tachycardia*)):ti,ab,kw of REFERENCE
or ((clozapin* or clozaril* or denzapin* or zaponex* or alemoxan
or azaleptin or clopine or clopsine or dorval or dozapine or elcrit
or fazaclo or “hf 1854” or hf1854 or lapen?x or lozapin* or sizopin
or versacloz or zapen) and tachycardia*):sin and (tachycardia*):
sco,spo of STUDY
The Cochrane Schizophrenia Group’s Register of Trials is com-
piled by systematic searches of major resources (including AMED,
BIOSIS, CINAHL, EMBASE, MEDLINE, PsycINFO, PubMed
and registries of clinical trials) and their monthly updates, hand-
searches, grey literature and conference proceedings (see Group
Module). There are no language, date, document type or publica-
tion status limitations for inclusion of records in the register.
Searching other resources
1. Other trials registers
On 28 February 2015, we searched the ClinicalTrials.gov register
of clinical trials (https://clinicaltrials.gov). Clinical trials entries
are delivered from the US National Institutes of Health. Please
see the attached link above to retrieve further details from the
government database.
2. Reference searching
We inspected the references of all included studies for further
relevant studies.
3. Personal contact
We also planned to contact the first author of each included study
for information regarding unpublished trials.
Data collection and analysis
Selection of studies
The principal review author JL, and review author MJD, inde-
pendently inspected all citations from the searches and identified
relevant abstracts. JM independently re-inspected these to ensure
reliability. JL and MJD obtained and inspected full reports of the
abstracts that met the review criteria. JM re-inspected these in or-
der to ensure reliable selection.Wewere not blinded to the name(s)
of the study author(s), their institution(s) or publication sources
at any stage of the review.
Data extraction and management
1. Extraction
Review authors JL and MJD independently extracted data from
all included studies. In addition, to ensure reliability, we planned
for JM to independently extract data from a random sample of
these studies, comprising 50% of the total. Again, any disagree-
ment would have been discussed, decisions documented and, if
necessary, we planned to contact the authors of the study for clar-
ification. However, this did not happen.
With remaining problems, we planned that JM would help clarify
issues and these final decisions would be documented. Data pre-
sented only in graphs andfigureswould be extractedwhenever pos-
sible, but included only if two review authors independently had
the same result. We planned to contact authors through an open-
ended request in order to obtain missing information or for clar-
ification whenever necessary. If studies were multi-centre, where
possible, we had planned to extract data relevant to each compo-
nent centre separately. However, we did not undertake these steps
as none of the studies fulfilled the review’s inclusion criteria.
2. Management
2.1 Forms
We extracted data onto standard, simple forms.
2.2 Scale-derived data
We planned to include continuous data from rating scales only if:
a) the psychometric properties of the measuring instrument had
been described in a peer-reviewed journal (Marshall 2000); and
b) the measuring instrument had not been written or modified by
one of the trialists for that particular trial.
Ideally, the measuring instrument should either be i. a self re-
port or ii. completed by an independent rater or relative (not the
therapist). We realise that this is not often reported clearly; in
’Description of studies’ we planned to note if this was the case or
not.
2.3 Endpoint versus change data
There are advantages of both endpoint and change data. Change
data can remove a component of between-person variability from
the analysis. On the other hand, calculation of change needs two
assessments (baseline and endpoint), which can be difficult in un-
stable and difficult to measure conditions such as schizophrenia.
We decided to primarily use endpoint data, and only use change
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data if the former were not available. Endpoint and change data
were to be combined in the analysis as we were going to use
mean differences (MD) rather than standardised mean differences
(SMDs) throughout (Higgins 2011).
2.4 Skewed data
Continuous data on clinical and social outcomes are often not
normally distributed. To avoid the pitfall of applying parametric
tests to non-parametric data, we aimed to apply the following
standards to data before inclusion:
We planned to enter data from studies of at least 200 participants,
for example, in the analysis irrespective of the following rules,
because skewed data pose less of a problem in large studies. We
also planned to enter change data, as when continuous data are
presented on a scale that includes a possibility of negative values
(such as change data), it is difficult to tell whether data are skewed
or not.We planned to present and enter change data into statistical
analyses
For endpoint data:
(a) When a scale starts from the finite number zero, we planned
to subtract the lowest possible value from the mean, and divide
this by the standard deviation. If this value is lower than 1, it
strongly suggests a skew and the study would have been excluded.
If this ratio is higher than one but below 2, there is suggestion of
skew. We decided to primarily use endpoint data, and only use
change data if the former were not available. Endpoint and change
data were to be combined in the analysis as we were going to use
mean differences (MD) rather than standardised mean differences
(SMDs) throughout (Altman 1996; Higgins 2011).
b) If a scale starts from a positive value (such as the Positive and
Negative Syndrome Scale (PANSS) (Kay 1986), which can have
values from 30 to 210), the calculation described above would
have been modified to take the scale starting point into account.
In these cases skew is present if 2 SD > (S-S min), where S is the
mean score and ’S min’ is the minimum score.
2.5 Common measure
To facilitate comparison between trials, we intended to convert
variables that can be reported in different metrics, such as days in
hospital (mean days per year, per week or permonth) to a common
metric (e.g. mean days per month).
2.6 Conversion of continuous to binary
Where possible, we planned to make efforts to convert outcome
measures to dichotomous data. This would be done by identifying
cut-off points on rating scales and dividing participants accord-
ingly into ’clinically improved’ or ’not clinically improved’. It is
generally assumed that if there is a 50%reduction in a scale-derived
score such as the Brief Psychiatric Rating Scale (BPRS, Overall
1962), or the Positive and Negative Syndrome Scale (PANSS, Kay
1986), this could be considered as a clinically significant response
(Leucht 2005; Leucht 2005a). If data based on these thresholds
were not available, we planned to use the primary cut-off presented
by the original authors.
2.7 Direction of graphs
Where possible, we planned to enter data in such away that the area
to the left of the line of no effect indicates a favourable outcome
for pharmacological interventions for clozapine-induced tachycar-
dia. Where keeping to this makes it impossible to avoid outcome
titles with clumsy double-negatives (e.g. ’not un-improved’), we
planned to report data where the left of the line indicates an un-
favourable outcome. This was to be noted in the relevant graphs.
Assessment of risk of bias in included studies
We includedno trials. If trials had been included, review authors JL
and MJD planned to work independently to assess risk of bias by
using the criteria described in the Cochrane Handbook for System-
atic Reviews of Interventions to assess trial quality (Higgins 2011).
This set of criteria is based on evidence of associations between
overestimate of effect and high risk of bias of the article such as se-
quence generation, allocation concealment, blinding, incomplete
outcome data and selective reporting.
If trials had been included JM would have independently assessed
a random sample of included trials for risk of bias, to ensure re-
liability. Again, if the raters had included trials, where there was
disagreement, the final rating was to be made by consensus, with
the involvement of JM. Where inadequate details of randomisa-
tion and other characteristics of trials were provided, we planned
to contact authors of the studies in order to obtain further infor-
mation. Non-concurrence in ’Risk of bias’ assessment was to be
reported, but if disputes arose as to which rating a domain was to
be allocated, resolution was to be made by discussion. The level
of risk of bias was to be noted in both the text of the review and
in the ’Summary of findings’ table, and reported in ’Risk of bias’
tables.
Measures of treatment effect
1. Binary data
For binary outcomes, we planned to calculate a standard estima-
tion of the risk ratio (RR) and its 95% confidence interval (CI).
It has been shown that RR is more intuitive than the odds ra-
tio (Boissel 1999), and that odds ratios tend to be interpreted
as RR by clinicians (Deeks 2000). The number needed to treat/
harm (NNTB/NNTH) statistic with its confidence intervals is
intuitively attractive to clinicians but is problematic both in its
accurate calculation in meta-analyses and interpretation (Hutton
2009). For binary data presented in the ’Summary of findings’
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table/s, where possible, we planned to calculate illustrative com-
parative risks.
2. Continuous data
For continuous outcomes, we planned to estimate the mean dif-
ference (MD) between groups. We preferred not to calculate effect
size measures (standardised mean difference (SMD)). However, if
scales of considerable similarity were used, we were going to pre-
sume there was a small difference in measurement, and we were
going to calculate the effect size and transform the effect back to
the units of one or more of the specific instruments.
Unit of analysis issues
1. Cluster trials
Studies increasingly employ ’cluster-randomisation’ (such as ran-
domisation by clinician or practice) but analysis and pooling of
clustered data poses problems. Firstly, authors often fail to account
for intra-class correlation in clustered studies, leading to a ’unit
of analysis’ error (Divine 1992), whereby P values are spuriously
low, confidence intervals unduly narrow and statistical significance
overestimated. This causes type I errors (Bland 1997; Gulliford
1999).
Where clustering was not accounted for in primary studies, we
planned to present data in a table, with a (*) symbol to indicate the
presence of a probable unit of analysis error. In subsequent versions
of this review, we will seek to contact first authors of studies to
obtain intra-class correlation coefficients (ICCs) for their clustered
data and to adjust for this by using accepted methods (Gulliford
1999). Where clustering had been incorporated into the analysis
of primary studies, we planned to present these data as if from a
non-cluster randomised study, but adjust for the clustering effect.
Statistical advice suggested the binary data as presented in a report
should be divided by a ’design effect’. This is calculated using
the mean number of participants per cluster (m) and the ICC
[Design effect = 1+(m-1)*ICC] (Donner 2002). If the ICC was
not reported, we would have assumed it to be 0.1 (Ukoumunne
1999).
If cluster studies had been appropriately analysed by taking into
account ICCs and relevant data documented in the report, synthe-
sis with other studies would be possible using the generic inverse
variance technique.
2. Cross-over trials
A major concern of cross-over trials is the carry-over effect. It oc-
curs if an effect (e.g. pharmacological, physiological or psycho-
logical) of the treatment in the first phase is carried over to the
second phase. As a consequence, on entry to the second phase the
participants can differ systematically from their initial state despite
a wash-out phase. For the same reason cross-over trials are not ap-
propriate if the condition of interest is unstable (Elbourne 2002).
As both effects are very likely in severe mental illness, we would
only have used data from the first phase of cross-over studies.
3. Studies with multiple treatment groups
Where a study involvedmore than two treatment arms, if relevant,
the additional treatment armswere to be presented in comparisons.
If data were binary these were to be simply added and combined
within the two-by-two table. If data were continuous we planned
to combine data following the formula in section 7.7.3.8 of the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011).Where the additional treatment arms were not relevant, we
would not have used these data.
Dealing with missing data
1. Overall loss of credibility
At some degree of loss of follow-up, data must lose credibility (Xia
2009). If, for any particular outcome, more than 50% of data were
unaccounted for, we planned not to reproduce these data or use
them within analyses. If, however, more than 50% of those in one
arm of a study were lost, but the total loss was less than 50%, we
were going to address this within the ’Summary of findings’ table/
s by downgrading quality. We also planned to downgrade quality
within the ’Summary of findings’ table/s should the loss be 25%
to 50% in total.
2. Binary
In the case where attrition for a binary outcome was between
0% and 50% and where these data were not clearly described,
we planned to present data on an intention-to-treat (ITT) basis.
Those leaving the study early would all be assumed to have the
same rates of negative outcome as those who completed, with
the exception of the outcome of death and adverse effects. For
these outcomes the rate of those who stayed in the study - in that
particular arm of the trial - was to be used for those who did not.
We planned to undertake a sensitivity analysis to test how prone
the primary outcomes were to change when data only from people
who completed the study to that point were compared to the ITT
analysis using the above assumptions.
3. Continuous
3.1 Attrition
In the case where attrition for a continuous outcome was between
0% and 50%, and data only from people who completed the study
to that point were reported, we planned to reproduce these.
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3.2 Standard deviations
If standard deviations (SDs) were not reported, we planned to first
try to obtain the missing values from the authors. If not avail-
able, where there were missing measures of variance for continu-
ous data, but an exact standard error (SE) and confidence intervals
were available for group means, and either P value or t value were
available for differences in mean, we planned to calculate them
according to the rules described in the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011).When only the SE
was reported, SDs are calculated by the formula SD = SE * square
root (n). Chapters 7.7.3 and 16.1.3 of the Cochrane Handbook for
Systematic Reviews of Interventions present detailed formulae for
estimating SDs from P values, t or F values, confidence intervals,
ranges or other statistics (Higgins 2011). If these formula did not
apply, we were going to calculate the SDs according to a validated
imputation method, which is based on the SDs of the other in-
cluded studies (Furukawa 2006). Although some of these impu-
tation strategies can introduce error, the alternative would be to
exclude a given study’s outcome and thus to lose information. We
nevertheless planned to examine the validity of the imputations
in a sensitivity analysis excluding imputed values.
3.3 Assumptions about participants who left the trials early
or were lost to follow-up
Various methods are available to account for participants who left
the trials early or were lost to follow-up. Some trials just present
the results of study completers, others use the method of last ob-
servation carried forward (LOCF), while more recently methods
such as multiple imputation or mixed-effects models for repeated
measurements (MMRM) have become more of a standard. While
the latter methods seem to be somewhat better than LOCF (Leon
2006), we feel that the high percentage of participants leaving the
studies early and differences in the reasons for leaving the stud-
ies early between groups is often the core problem in randomised
schizophrenia trials. We therefore planned not to exclude stud-
ies based on the statistical approach used. However, we preferred
to use the more sophisticated approaches. For example, where
MMRM or multiple-imputation data were reported, we planned
to use these in preference to LOCF, and completer analyses would
have only been presented if some kind of intention-to-treat data
were not available at all.Moreover, we planned to address this issue
in the ’incomplete outcome data domain of the ’Risk of bias’ tool.
Assessment of heterogeneity
1. Clinical heterogeneity
We planned to consider all included studies initially, without see-
ing comparison data, to judge clinical heterogeneity. We were to
simply inspect all studies for clearly outlying people or situations
that we had not predicted would arise. When such situations or
participant groups arose, these were to be fully discussed.
2. Methodological heterogeneity
We planned to consider all included studies initially, without see-
ing comparison data, to judge methodological heterogeneity. We
planned to inspect all studies for clearly outlying methods that we
had not predicted would arise. When such methodological out-
liers arose, these were to be fully discussed.
3. Statistical heterogeneity
3.1 Visual inspection
We planned to visually inspect graphs to investigate the possibility
of statistical heterogeneity.
3.2 Employing the I2 statistic
We planned to investigate heterogeneity between studies by con-
sidering the I2 statistic alongside the Chi2 P value. The I2 statistic
provides an estimate of the percentage of inconsistency thought to
be due to chance (Higgins 2003). The importance of the observed
value of I2 depends on (1) the magnitude and direction of effects,
and (2) the strength of evidence for heterogeneity (e.g. P value
from Chi2 test, or a confidence interval for I2). An I2 estimate
greater than or equal to around 50%, accompanied by a statisti-
cally significant Chi2 result, was to be interpreted as evidence of
substantial levels of heterogeneity (Section 9.5.2 - Higgins 2011).
When substantial levels of heterogeneity were found in the pri-
mary outcome, we planned to explore the reasons for heterogene-
ity (Subgroup analysis and investigation of heterogeneity).
Assessment of reporting biases
1. Protocol versus full study
Reporting biases arise when the dissemination of research findings
is influenced by the nature and direction of results (Egger 1997).
These are described in section 10.1 of the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). We planned to
locate protocols for included randomised trials. If the protocol was
available, outcomes in the protocol and in the published report
were to be compared. If the protocol was not available, the out-
comes listed in the methods section of the trial report were to be
compared with the reported results.
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2. Funnel plot
We are aware that funnel plots may be useful in investigating
reporting biases but are of limited power to detect small-study
effects. We planned not to use funnel plots for outcomes where
there were 10 or fewer studies, or where all studies were of similar
sizes. In other cases, where funnel plots were possible, we planned
to seek statistical advice in their interpretation.
Data synthesis
We understand that there is no closed argument for preference for
use of fixed-effect or random-effects models. The random-effects
method incorporates an assumption that the different studies are
estimating different, yet related, intervention effects. This often
seems to be true to us and the random-effects model takes into
account differences between studies even if there is no statistically
significant heterogeneity. There is, however, a disadvantage to the
random-effects model. It puts added weight onto small studies,
which often are the most biased ones. Depending on the direction
of effect, these studies can either inflate or deflate the effect size.
We planned to apply the fixed-effect model for all analyses. The
reader is, however, able to choose to inspect the data using the
random-effects model.
Subgroup analysis and investigation of heterogeneity
1. Subgroup analyses
1.1 Primary outcomes
Subgroup analyses would have been performed, if possible, to anal-
yse for different components of the intervention for clozapine-
associated tachycardia, including: different types of medication
used, different doses of medication used and mode of medication
administration
1.2 Clinical state, stage or problem
We proposed to undertake this review and provide an overview of
the effects of pharmacological intervention for clozapine-induced
tachycardia for people with schizophrenia and psychotic disorders
in general. In addition, we had sought to try to report data on
subgroups of people in the same clinical state, stage and with
similar problems.
2. Investigation of heterogeneity
If inconsistency was high, this would have been reported. First, we
planned to investigate whether data had been entered correctly.
Second, if data were correct, thenwewould have visually inspected
the graph and outlying studies would have been successively re-
moved to see if homogeneity was restored. For this review, we had
planned that should this occur with data contributing to the sum-
mary finding of no more than around 10% of the total weighting,
wewould present the data. If not, thenwe planned that data would
not be pooled and the issues would be discussed. We know of no
supporting research for this 10% cut-off but are investigating use
of prediction intervals as an alternative to this unsatisfactory state.
When unanticipated clinical or methodological heterogeneity was
obvious, we planned to simply state hypotheses regarding these
for future reviews or versions of this review. We did not anticipate
undertaking analyses relating to these.
Sensitivity analysis
1. Implication of randomisation
We aimed to include trials in a sensitivity analysis if they were
described in some way as to imply randomisation. For the primary
outcomes, we would have included these studies and if there was
no substantive difference when the implied randomised studies
were added to those with better description of randomisation, then
all data would have been employed from these studies.
2. Assumptions for lost binary data
Where assumptions had to bemade regardingpeople lost to follow-
up, or missing SDs (see Dealing with missing data), we planned
to compare the findings of the primary outcomes when we used
our assumption compared with completer data only. If there was a
substantial difference, we planned to report the results and discuss
them but continue to employ our assumption.
3. Risk of bias
We planned to analyse the effects of excluding trials that were
judged to be at high risk of bias across one or more of the domains
of randomisation (implied as randomised with no further details
available), allocation concealment, blinding and outcome report-
ing for the meta-analysis of the primary outcome. If the exclusion
of trials at high risk of bias did not substantially alter the direction
of effect or the precision of the effect estimates, then data from
these trials were to be included in the analysis.
4. Imputed values
We planned to undertake a sensitivity analysis to assess the effects
of including data from trials for which we used imputed values for
ICC in calculating the design effect in cluster-randomised trials.
If we had noted substantial differences in the direction or precision
of effect estimates in any of the sensitivity analyses listed above,
we would not pool data from these excluded trials with those of
other trials contributing to the outcome but would have presented
them separately.
12Pharmacological interventions for clozapine-induced sinus tachycardia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
5. Fixed-effect and random-effects
We planned to synthesise all data using a fixed-effect model, how-
ever, we would have also synthesised data for the primary outcome
using a random-effects model to evaluate whether this would have
altered the significance of the results.
R E S U L T S
Description of studies
We did not find any studies that fulfilled the inclusion criteria.
Results of the search
We found three records through electronic searching of the
Cochrane Schizophrenia Register up toMarch 2015; none of these
were duplicates leaving three records for screening (Figure 1). Af-
ter screening, we obtained the three full-text articles for further
assessment. These were closely assessed for inclusion, but none
could eventually be included in the review. These three studies,
Liang 2001,Wang 1995 andWei 1995, are in the excluded studies
table (Characteristics of excluded studies).
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Figure 1. Study flow diagram.
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Searches of trial registries identified one ongoing and eligible
trial in this area (NCT00882856) (https://clinicaltrials.gov/show/
NCT00882856).
Awaiting assessment studies
There are no studies awaiting assessment.
Ongoing studies
We know of one ongoing trial (NCT00882856).
Included studies
There are no included studies in this review.
Excluded studies
We assessed three studies carefully for inclusion, but excluded all
of them as none specified treatment for clozapine-induced tachy-
cardia. The three excluded trials used interventions for antipsy-
chotic-induced tachycardia, without specifically identifying treat-
ment for clozapine-induced tachycardia (Liang 2001;Wang 1995;
Wei 1995).
Risk of bias in included studies
No studies could be included in this review, hence we were unable
to assess risk of bias.
Effects of interventions
See: Summary of findings for the main comparison
Pharmacological interventions for clozapine-induced tachycardia
No study met the inclusion criteria. The excluded studies demon-
strate that trials of pharmacotherapeutic interventions for antipsy-
chotic-induced tachycardia are possible, however no trials com-
paring interventions specifically for clozapine-induced tachycar-
dia have been conducted. We had hoped to gather information
on global and mental state, issues around use of services, quality
of life, satisfaction with treatment and costs. Such data are not
available from randomised trials.
D I S C U S S I O N
Summary of main results
We did not find any study that compared treatments for cloza-
pine-induced tachycardia. Three randomised studies used some
form of pharmacotherapeutic intervention for antipsychotic-in-
duced tachycardia, but did not specify response for those on cloza-
pine or did not include patients treated with clozapine (Liang
2001; Wang 1995; Wei 1995). We further identified one retro-
spective chart review (Stryjer 2009), and four case reports (Das
2014; Lally 2014; van Dam 2012) , which reported on the use
of beta-blockers (Stryjer 2009; van Dam 2012), ivabradine (Lally
2014), and verapamil (Das 2014) in the treatment of clozapine-
induced tachycardia. These studies could be relevant in guiding
the management of clozapine-induced tachycardia, but none met
the review’s inclusion criteria.
Overall completeness and applicability of
evidence
There is currently no randomised trial-based evidence.
Quality of the evidence
There is currently no randomised trial-based evidence.
Potential biases in the review process
We limited potential biases in the review process by following the
Cochranemethodology.The search for trialswas thoroughwith no
language, date, document type or publication status limitations.
We strictly followed the review protocol in the process of study
selection, data extraction and analysis.
Agreements and disagreements with other
studies or reviews
We know of no other reviews focusing on this intervention.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
1. For people with clozapine-induced tachycardia
Despite the fact that clozapine-induced tachycardia is a common
adverse effect, in this review we were unable to identify studies
that compared interventions for its treatment. However, this re-
view does indicate that trials in this area are possible. Pharmaco-
logical interventions for this troublesome adverse effect have not
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been adequately investigated within the context of a trial and this
needs to be addressed. People with clozapine-induced tachycardia
could encourage this investigation or support it by agreeing to be
randomised to well-designed and reported studies.
2. Clinicians
Despite growing interest in the management of the adverse events
associatedwith clozapine use, the literature in the area of treatment
for clozapine-induced tachycardia is still very limited. Researchers
and clinicians have undertaken studies, but these studies fall well
short of rigorous trials. A retrospective chart review demonstrated
that atenolol had increased effectiveness and better tolerability
than propranolol in controlling tachycardia associated with cloza-
pine therapy (Stryjer 2009). Two case reports described the use of
ivabradine to effectively treat clozapine-induced tachycardia and
reported that it was well tolerated (Lally 2014). A further case re-
port described the use of verapamil to effectively treat clozapine-
induced tachycardia (Das 2014). However, this evidence is fully
open to biases with the potential harm that these can bring.
It seems that clinicians have no choice but to continue with their
current practice, based on clinical judgement, because of the lack
of randomised evidence to help guide their choice of intervention.
Clinicians have a responsibility to lobby for and help good research
in this area.
3. For policymakers
Clinical practice guidelines should include the best available evi-
dence. Currently, however, there is insufficient evidence from tri-
als on which to base guidelines for the treatment of clozapine-
induced tachycardia. It could be suggested as policy that in such
cases clinical practice should take place within well-designed trials.
Implications for research
1. General
Clinicallymeaningful randomised studies are needed to help guide
clinicians in their management of clozapine-induced tachycardia.
Available publications indicate that such studies are possible. There
is a need for randomised trials to compare pharmacotherapeu-
tic interventions for clozapine-induced tachycardia. These trials
should focus on the treatment of tachycardia with a focus on pa-
tient tolerability and satisfaction with the intervention, along with
consideration of clinical state outcome measures. Validated mea-
sures regarding the primary outcome and adverse effects should
be used.
2. Specific
Pragmatic, real world randomised controlled trials should be car-
ried out to determine the value of possible treatments for clozap-
ine-induced tachycardia in standard clinical practice. Studies need
to have a duration longer than one month and involve people
whose problems are clearly documented, whether by clinical mea-
surement of pulse rate, electrocardiogram (ECG) recordings or
from case records. The methods should be very clearly described
and tested and the interventions should probably involve the use
of a placebo, however the best chosen experimental treatment may
be one that is used or accepted locally. From this review a beta-
blocker may be indicated as a first-line intervention for investiga-
tion; based on practice in the UK, this could be bisoprolol. Stud-
ies need to include a validated method of measuring clozapine-
induced tachycardia and some medium- and long-term outcomes
including adverse events (specifically hypotension and bradycar-
dia), discontinuation of treatment and satisfaction with treatment.
We have suggested a design for a study in Table 1.
A C K N OW L E D G E M E N T S
The Cochrane Schizophrenia Group Editorial Base in Notting-
ham produces and maintains standard text for use in the Methods
section of their reviews. We have used this text as the basis of what
appears here and adapted it as required.
The search termswere developed by the Trials SearchCo-ordinator
of the Cochrane Schizophrenia Group and the contact author of
this protocol.
We wish to thank Tang Xudong for the helpful comments on an
earlier draft of the protocol, as well as Debbie Chido, Mohamad
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Liang 2001 Allocation: randomised (no further detail)
Participants: diagnosis not stated; only stated that participants were taking antipsychotics
Intervention: Tian-wang-bu-xin-dan (Chinese traditional medicine) versus propranolol; clozapine not specified as a
treatment used
Wang 1995 Allocation: randomised (no further detail)
Participants: schizophrenia inpatients with tachycardia; n = 100; male and female; 18 to 60 years of age
Intervention: propranolol versus verapamil; clozapine use not specified
Wei 1995 Allocation: randomised (no further detail)
Participants: 100 people diagnosed with schizophrenia; all had sinus tachycardia induced by antipsychotic drugs
Intervention: propranolol 10 mg 3 times a day versus verapamil 20 mg 3 times a day, each for 2 weeks; investigated the
effects of propranolol and verapamil for antipsychotic-induced tachycardia and did not investigate clozapine-induced
tachycardia specifically
Characteristics of ongoing studies [ordered by study ID]
NCT00882856
Trial name or title ’Treating clozapine-induced sinus tachycardia with bisoprolol - a double blinded placebo controlled cross over
study’
Methods Allocation: randomised
Endpoint classification: safety/efficacy study
Intervention model: cross-over assignment
Masking: double-blind (subject, caregiver, investigator, outcomes assessor)
Primary purpose: treatment
Participants 36 individuals with a diagnosis of schizophrenia or schizoaffective disorder on clozapine
Age: over 18 to 65
Sex: both male and female
All with clozapine-induced sinus tachycardia
Inclusion criteria:
• Treated with clozapine > 3 months and minimum 100 mg/day
• Fixed dose 14 days before inclusion
• Heart rate > 100 (ECG)
• Pregnancy test negative
• Clozapine-induced sinus tachycardia documented by ECG or case record
• Sexual abstinence or contraception
• Informed consent
Exclusion criteria:
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NCT00882856 (Continued)
• Substance abuse
• Physical diseases, contraindications for clozapine or bisoprolol
• Asthma or chronic obstructive lung disease
• Blood pressure < 100/60 or recent history of syncope
• QTc > 500 ms, SA-block, AV- block II or III
• Restrictions by Danish mental act
• Allergic to clozapine or bisoprolol
Interventions Bisoprolol 10 mg daily compared with placebo for the treatment of clozapine-induced sinus tachycardia
Outcomes Primary outcome measures:
• Heart rate variability (time frame: baseline, visit 1 + 2 + 3) (designated as safety issue: no)
Secondary outcome measures:
• QTc, T-wave morphology and other ECG markers (time frame: baseline, visit 1 + 2 + 3) (designated as
safety issue: yes)
• Hamilton Anxiety Scale (time frame: baseline, visit 1 + 2 + 3) (designated as safety issue: no)
• Salivation rate (time frame: baseline, visit 1 + 2 + 3) (designated as safety issue: no)
• Orthostatic blood pressure (time frame: baseline, visit 1 + 2 + 3) (designated as safety issue: yes)
• WHO QoL (time frame: baseline, visit 1 + 2 + 3) (designated as safety issue: no)
• Nocturnal Hypersalivation Rating Scale (NHRS) (time frame: baseline, visit 1 + 2 + 3) (designated as
safety issue: no)
Starting date 16 April 2009
Contact information Contact: Jimmi Nielsen, MD; Contact: Sonja Snel, MD
Notes Principal Investigator: Dr Jimmi Nielsen, PhD, Aalborg Psychiatric Hospital
Sponsor: University of Aarhus
ECG: electrocardiogram
QoL: quality of life
WHO: World Health Organization
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. Suggested design for trials
Methods Participants Interventions Outcomes Notes
Allocation: centralised
sequence generation
with table of random
numbers or computer
generated code
Sequence
concealed until interven-
tions
assigned
Diagnosis: treatment-re-
sistant schizophrenia,
schizoaffective disorder
or other psychotic dis-
orders for which longer-
term clozapine
treatment is
indicated and who have
devel-
oped sustained clozap-
ine-induced tachycardia
1. Bisoprolol 5 mg to 10
mg 3 times a day
2. Placebo: flexible dose
or
1. Ivabradine 5 mg to 7.
5 mg twice a day
2. Placebo: flexible dose
1. Measurement of pulse
rate
1.1 Normalisation of
pulse rate (as defined by
a pulse rate < 100 beats/
minute or by the individ-
ual studies)
1.2 Clinically important
change in pulse rate
(as defined by individual
studies)
1.
3 Mean change in pulse
rate documented by elec-
trocardiogram (ECG) or
from case record
1.4Mean endpoint pulse
rate
documented by ECG or
from case record
Secondary outcomes:
2. ECG measurement
2.1 Heart rate and
rhythm
2.2 QTc interval
2.3 T-wave morphology
2.4 Other ECG markers
Size of study to detect
a 10% difference in
improvement with 80%
certainty
Blinding: participants,
those recruiting
and assigning partici-
pants,
those assessing
outcomes will be blind
to treatment allocation
Blinding can be tested by
asking participants and
raters to guess the treat-
ment
they were exposed
to
All with clozapine-in-
duced sinus tachycardia
Age: adults. 18 to 65
years
Sex: men and women
Setting: hospital and
community
- 1. Adverse effects-spe-
cific, such as hypoten-
sion and bradycardia
2. Discontinuation of
treatment
3. Satisfactionwith treat-
ment
4. Service outcomes
5. Global state
6. Mental state (with
particular reference to
the positive symptoms of
-
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Table 1. Suggested design for trials (Continued)
schizophrenia)
7. Cost
Duration: minimum of
1 year
Inclusion criteria:
• Treated with
clozapine > 3 weeks and
minimum 100 mg/day
• Heart rate > 100
(ECG)
• Pregnancy test
negative
• Clozapine-induced
sinus tachycardia
documented by ECG or
case record
Exclusion criteria:
• Substance abuse
• Physical illnesses,
contraindications for
bisoprolol or ivabradine
• Asthma or chronic
obstructive lung disease
(if beta-blocker used)
• Blood pressure <
100/60 or recent history
of syncope
• QTc > 500 ms,
SA-block, AV- block II
• Allergic to
bisoprolol or ivabradine
- - -
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